Abstract 196P
Background
High-grade serous ovarian carcinoma (HGSOC) remains the deadliest gynecologic malignancy, primarily due to its asymptomatic nature in the early-stages and the complex, poorly understood mechanisms driving its progression.
Methods
In this study, we employed single-cell RNA-seq analysis to delve deeper into early-stage of HGSOC, uncovering a previously underappreciated dominant infiltration and heterogeneity of regulatory T (Treg) cells.
Results
Within the HGSOC lesions, we detected CD4 regulatory T cells (Tregs) displaying diverse transcriptomic profiles indicative of their naïve, effector, proliferating, and destabilized states. The presence of Tregs was associated with an immunosuppressive tumor microenvironment, featured by CD4 Th2 cells, exhausted CD8 T cells, lacking cytotoxicity NK cells, and tumor-associated macrophages (TAMs). Cell-to-cell communication analysis predicted Treg-mediated inhibition of immune responses and reciprocal interactions with tumor cells promoting Treg activation. Trajectory analysis revealed two Treg differentiation paths, both leading to immunosuppressive FOXP3high and FOXP3+ Treg profiles. Notably, while the trajectory of FOXP3high profile converges with proliferating Tregs, the second path of cytotoxic FOXP3+ Tregs aligned with FOXP3- ex-Tregs, distinguished by an anti-tumor CXCL13+IFNG+ transcriptomic profile.
Conclusions
Therefore, despite the immunosuppressive environment, we identified the counteracting antitumor activity of Tregs, highlighting the potential of manipulating Treg cell fate as for therapeutic strategies.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session